



# 2Eyes Vision

Challenging the premium ophthalmology market with disruptive products

Susana Marcos, PhD

**ESCRS** iNovation® Day

6<sup>th</sup> September 2024 Barcelona

# SimVis Gekko™

A revolutionary technology for an accurate and personalized experience of premium cataract and presbyopic corrections.

Patients can see the real world before surgery/treatment











## **Programmable | See-through | Binocular | Head-Mounted | Wireless**

## We have >25 scientific publications...









The concept

The miniaturized device

simulations



Binocular device

... and 5 patents protecting our technology














# SimVis technology is able to predict of IOL performance accurately and increase conversion rate to multifocality

# **Prediction of IOL performance with SimVis Gekko (n=15)**









Optical Defocus (D)

# Performance of several IOLs for one same subject



# **Increased conversion rate**

- SimVis Gekko increased the conversion rate to multifocality (trifocal or EDOF) in an 86%
- **Economic factor was removed from the equation**. The IOLs implanted were covered by the Public National Health System
- Patients were shown all the options (monofocal, trifocal and EDOF) and a consensual decision was made between patients and the surgeon after trying SimVis Gekko





2EyesVision



# SimVis also predicts glare and visual disturbances

SimVis Gekko proved to be a sensitive tool to demonstrate differences in photic phenomena across different multifocal IOLs prior to surgery





The **size of the glare** through the visual simulator with each of the presbyopic corrections tested was **highly correlated** (rs > 0.97) **with the reported symptoms perceived** 

Glare



**Rings and Spider Webs** 



Hazy vision



How much were you bothered?

- Not at all
- ☐ A Little
- Somewhat
- Quite a bit
- □ Extremely


ESCRS 2024 Papadogiannis



# 2EyesVision is raising 2 million € to reach breakeven by 2026 and to become the top-of-mind in the visual simulation field

Milestones for 2024-2028

# Financing round opened2 million €






- 6.5 M€ in revenues
- 2,5 M€ EBITDA (39%)
- 33 employees
- 479 Units sold



#### 2028

- 12 M€ in revenues
- 6 M€ EBITDA (52%)
- 42 employees
- 911 Units sold



## 2024

- 520.000€ in revenues
- 40 units sold
- 19 employees
- SimVis 4.0 launch
- Signature of 6 new distribution agreements

### 2025

- 1,5 M€ in revenues
- 111 units sold
- 23 employees
- Signature of 5 new distribution agreements

#### 2026

- 3,5 M€ in revenues
- Positive EBITDA (>0,5 M€)
- · 259 units sold
- 25 employees
- Signature of 4 new distribution agreements

#### 50 SimVis in 18 countries around the world in 2024



2EyesVision